FDA Clearance Tracker · P130022-S039
Senza Spinal Cord Stimulation (SCS) System
Last checked: Nov 20, 2026Latest source record: Jul 16, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jul 16, 2021
Approved
Time to decision
200 days
Received Dec 28, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130022-S039
- Device name
- Senza Spinal Cord Stimulation (SCS) System
- Applicant
- Nevro Corporation
- Applicant location
- Redwood City, CA
- Received
- Dec 28, 2020
- Decided
- Jul 16, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130022
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Senza Spinal Cord Stimulation (SCS) System for expanding the indications to add the following: The Senza®, Senza II and Senza Omnia neuromodulation systems, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy.
Source documents
Other decisions for Nevro Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S042 · Decided Jan 18, 2022 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.